Estrella Immunopharma Changes Fiscal Year End
Ticker: ESLAW · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1844417
Sentiment: neutral
Topics: fiscal-year-change, administrative
Related Tickers: ESLA
TL;DR
ESLA changed its fiscal year end to 12/31. New reporting cycle starts now.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on November 26, 2024, reporting a change in its fiscal year end to December 31st. The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates a potential shift in the company's financial reporting cadence, which could impact how investors track its performance and compare it to industry peers.
Risk Assessment
Risk Level: low — The filing is a routine administrative update regarding the company's fiscal year end and does not involve significant financial transactions or strategic changes.
Key Numbers
- 1231 — Fiscal Year End (Updated to December 31st)
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- November 25, 2024 (date) — Date of earliest event reported
- December 31 (date) — New Fiscal Year End
- TradeUP Acquisition Corp. (company) — Former Company Name
- February 4, 2021 (date) — Date of Name Change
FAQ
What is the new fiscal year end for Estrella Immunopharma, Inc.?
The new fiscal year end for Estrella Immunopharma, Inc. is December 31st.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 25, 2024.
What was Estrella Immunopharma, Inc. formerly known as?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
On what date did the company change its name from TradeUP Acquisition Corp.?
The company changed its name on February 4, 2021.
What is the Standard Industrial Classification (SIC) code for Estrella Immunopharma, Inc.?
The SIC code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-11-26 17:00:09
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea0222615-8k_estrella.htm (8-K) — 30KB
- 0001213900-24-102899.txt ( ) — 247KB
- esla-20241125.xsd (EX-101.SCH) — 4KB
- esla-20241125_def.xml (EX-101.DEF) — 26KB
- esla-20241125_lab.xml (EX-101.LAB) — 36KB
- esla-20241125_pre.xml (EX-101.PRE) — 25KB
- ea0222615-8k_estrella_htm.xml (XML) — 6KB
03. Amendments to Articles of Incorporation or Bylaws; Change
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 25, 2024, in order to align the fiscal year of Estrella Immunopharma, Inc. (the " Company ") with the calendar year and facilitate the Company's accounting and reporting processes, the Board of Directors of the Company approved a change in the Company's fiscal year end from June 30 to December 31. As a result of this change, the Company will have a transition period from July 1, 2024 to December 31, 2024. The Company expects to file a transition report on Form 10-KT with the Securities and Exchange Commission, including audited financial statements for the transition period. Item9.01 Financial Statements and Exhibits. (d)Exhibits 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESTRELLA IMMUNOPHARMA, INC. Date: November 26, 2024 By: /s/ Cheng Liu Name: Cheng Liu Title: Chief Executive Officer 2